文献速递其他结缔组织病血管炎

欧洲心脏病学会风险评估评分在系统性硬化症相关肺动脉高压中的评估

Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-04-22

研究应用2022年欧洲心脏病学会(ESC)风险分层工具,在260例系统性硬化症相关肺动脉高压(SSc-PAH)患者基线和随访时评估。基线时72.2%为中危,随访时55.5%为低危或中低危;该工具在随访时能区分风险层间的生存率,三个参数均与死亡率相关。结论认为该策略可预测生存,治疗决策应包含风险评估以达低危状态。

要点

  • 基线时72.2%的SSc-PAH患者被2022年ESC工具评为中危。
  • 随访时55.5%的患者被分类为低危或中低危。
  • 随访时2022年风险模型能区分风险层间的生存率。

核心结论

  • 2022年ESC风险评估策略在基线和随访时应用可预测SSc-PAH的生存。
  • SSc-PAH的治疗决策应包含风险评估,旨在达到2022年ESC指南的低危状态。

研究设计与样本

  • 多国新发系统性硬化症相关肺动脉高压(SSc-PAH)队列研究。
  • 在基线和随访(2年内)应用2022年ESC风险评估工具。
  • 采用Kaplan-Meier曲线、Cox hazards回归和加速失效时间模型评估风险评分与生存的关系。

主要发现

  • 基线时(n=260),72.2%的SSc-PAH患者根据2022年工具评为中危。
  • 随访时,根据2022年工具,55.5%的队列分类为低危或中低危。
  • 2022年风险模型在随访时能区分风险层间的生存率。
  • 世界卫生组织功能分级、N末端脑钠肽前体和六分钟步行距离三个参数在基线和/或随访时均与死亡率显著相关。

临床怎么用

  • 作者结论认为,SSc-PAH的治疗决策应包含风险评估,旨在达到2022年ESC指南的低危状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with pulmonary arterial hypertension (PAH) may be stratified as low, intermediate, or high risk of 1-year mortality. In 2022, the European Society of Cardiology (ESC) updated and simplified its risk stratification tool, based on three variables: World Health Organization functional class, serum N-terminal pro-brain type natriuretic peptide and six-minute walk distance, applied at follow-up visits, intended to guide therapy over time. METHODS: We applied the 2022 ESC risk assessment tool at baseline and follow-up (within 2 years) to a multinational incident cohort of systemic sclerosis-associated PAH (SSc-PAH). Kaplan-Meier curves, Cox hazards regression, and accelerated failure time models were used to evaluate survival by risk score. RESULTS: At baseline (n = 260), the majority of SSc-PAH (72.2%) were graded as intermediate risk of death according to the 2022 tool. At follow-up, according to 2022 tool, half (55.5%) of the cohort were classified as low or intermediate-low risk. The 2022 risk model at follow-up was able to differentiate survival between risk strata. All three individual parameters (World Health Organization functional class, N-terminal pro-brain type natriuretic peptide, six-minute walk distance) were significantly associated with mortality at baseline and/or follow-up. CONCLUSION: The 2022 ESC risk assessment strategy applied at baseline and follow-up predicts survival in SSc-PAH. Treatment decisions for SSc-PAH should include risk assessments, aiming to achieve low-risk status according to the 2022 ESC guidelines.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Brown Z, Hansen D, Stevens W, et al. Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Arthritis Care Res (Hoboken). 2024. PMID: 38523256. doi:10.1002/acr.25328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。